Abstract
MicroRNAs (miRNAs) have emerged as promising biomarkers in cancer diagnosis and prognosis, including breast cancer (BC). In this study, we examine whether miR-1256 may be regarded as a powerful biomarker for predicting the prognosis of BC. The expression of miR-1256 was detected in 30 formalin-fixed paraffin-embedded (FFPE) tissue pairs of tumoral samples and their non-tumoral tissues using qRT-PCR. The clinicopathological characteristics of patients relative to miR-1256 expression, along with fold change analysis employing the 2-ΔΔCT method, were also investigated. All statistical analyses were conducted using GraphPad Prism and MedCalc. We found that the miR-1256 level in BC FFPE tissues is notably increased with p < 0.006 and a (2.5367)-fold change compared to control tissues. Also, we analyzed the association between the expression level of miR-1256 and the clinicopathological parameters of BC patients. The overexpression of miR-1256 exhibited no significant correlation with age, tumor grade, tumor size, estrogen receptor (ER) status, human epidermal growth factor-2 (Her-2), or tumor, node, metastasis (TNM) status among patients. The progesterone receptor (PR) status suggested a potential trend (P = 0.077), indicating that low miR-1256 expression was more common in PR-positive subjects. Moreover, the p-value, area under the curve (AUC), Std. Error, sensitivity, and specificity are (0.7039, 0.06709, 0.67, and 0.7, respectively), this signifies a moderate capacity of the test to differentiate between tumors with controls. The results of fold change analysis employing the 2-ΔΔCT method indicated a (2.5367)-fold elevation in miR-1256 expression in tumors relative to controls. This suggests that miR-1256 may have an oncogenic role in carcinogenesis, potentially promoting BC development. As a result, we demonstrated that elevated miR-1256 expression correlates with the progression of BC, indicating that miR-1256 may be associated with oncogenic processes in BC tumorigenesis and progression.
Keywords
Breast Cancer
miR-1256
Prognostic Biomarker